Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.
J Clin Gastroenterol. 2012 Oct;46 Suppl:S67-8. doi: 10.1097/MCG.0b013e3182647a49.
In 2011, the Committee on Nutrition of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition systematically reviewed published evidence on the safety and health effects of the administration of formulae supplemented with probiotics and/or prebiotics compared with unsupplemented formulae. The document could serve as an example of problems relating to the choice and definition of outcomes assessing the addition of new ingredients to infant formulae. The studies were often too small with insufficient power to identify relevant effects, and the follow-up periods in the trials were too short. The clinical outcomes, even those relating to the same domain (eg, gastrointestinal infections) differed. Even if the same outcomes were measured, the definitions of the outcomes were heterogenous, often not widely agreed upon, or just lacking. The use of inappropriate outcome measures and/or their definitions may result in misleading conclusions. It may also lead to an overestimation or underestimation of potential benefits of the intervention or fail to reveal any potential benefits. There is a need for well-designed and carefully conducted randomized controlled trials, with relevant inclusion/exclusion criteria and adequate sample sizes. These studies should use validated clinical outcome measures.
2011 年,欧洲儿科胃肠病学、肝病学和营养学会营养委员会系统地回顾了已发表的关于添加益生菌和/或益生元配方与未添加配方的比较的安全性和健康影响的证据。该文件可以作为与选择和定义评估婴儿配方中添加新成分的结果相关的问题的一个例子。这些研究往往规模太小,没有足够的能力来确定相关影响,而且试验的随访时间太短。临床结果,即使是涉及同一领域(例如,胃肠道感染)的结果,也存在差异。即使测量了相同的结果,其定义也存在差异,往往没有广泛达成一致,或者只是缺乏共识。使用不适当的结果测量方法和/或其定义可能会导致误导性的结论。这也可能导致对干预措施的潜在益处的高估或低估,或者无法揭示任何潜在的益处。需要进行精心设计和精心实施的随机对照试验,纳入/排除标准相关且样本量足够。这些研究应使用经过验证的临床结果测量方法。